This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included.
This paper [
The paper can be improved in certain areas like methods and design. Also, there is some duplication of the results in the discussion.
Inclusion criteria need to be well defined.
Initial HFNT (high-flow nasal therapy) settings: there is a discrepancy between the flow mentioned in the Method and Design section (35 L/min) and that mentioned in the Results section (33.5, SD 11.7 L/min of flow). Can you please clarify?
The discussion needs to be rewritten. It seems like a duplication of the results, especially the first paragraph.
The dose of methylprednisolone should read “mg/kg.”
Screening criteria: were the patients identified with high clinical suspicion based on computed tomography COVID-19 negative? If yes, please mention that in the paper.
In the sentence, “At initiation of HFNC, a ROX of <5 was predictive of intubation (OR 2.137,
In the sentence, “Any change in ROX of less than or equal to zero after HFNT initiation over 24 hours was also predictive of intubation,” what do you mean by change less than or equal to zero? This sentence is a little confusing.
There are multiple references of ROC=0.77 and ROC=0.86; did you mean AUC (area under the ROC curve) or C-statistic?
None declared.